November 17, 2016 / 12:52 PM / a year ago

BRIEF-ProMetic's PBI-4050 Demonstrates Early Evidence of Efficacy in its Idiopathic Pulmonary Fibrosis Phase 2 Clinical Trial

Nov 17 (Reuters) - ProMetic Life Sciences Inc

* ProMetic’s PBI-4050 demonstrates early evidence of efficacy in its idiopathic pulmonary fibrosis (“IPF”) phase 2 clinical trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below